Pharmacotherapeutics for Advanced Practice
Nurse Prescribers with Davis Edge
6th Edition
TEST BANK
Reference: Ch. 1, Section: The Role of the Advanced Practice
Nurse as Prescriber
Question Stem: An experienced APRN evaluates a new patient
with hypertension who is taking an over-the-counter herbal
supplement. Which action best reflects the APRN’s prescribing
responsibility?
A. Advise stopping all supplements and prescribe
antihypertensive medication immediately.
B. Document the supplement in the medication reconciliation,
assess for interactions, and consider this when selecting
therapy.
C. Ignore the supplement because OTC and herbal products are
not regulated the same as prescription drugs.
D. Refer the patient to a pharmacist and avoid prescribing until
the pharmacist assesses interactions.
Correct Answer: B
Rationale:
, • Correct (B): APRNs must perform medication
reconciliation, document OTC/herbal products, assess for
drug–drug interactions, and integrate this information into
rational drug selection; this aligns with safe prescribing
principles.
• Incorrect (A): Automatically stopping supplements without
assessment may harm rapport and is not evidence-based;
prescribers should evaluate risks/benefits first.
• Incorrect (C): OTC/herbal agents can interact with
prescribed drugs; dismissing them is unsafe.
• Incorrect (D): Collaboration with pharmacists is
appropriate, but the APRN retains responsibility for
prescribing decisions and should not abdicate them.
Teaching Point: Always reconcile and assess OTC/herbal
products before prescribing.
Citation: Woo TM & Wright WL. Ch. 1, The Role of the
Advanced Practice Nurse as Prescriber. VitalSource+1
2
Reference: Ch. 1, Section: The Role of the Advanced Practice
Nurse as Prescriber
Question Stem: A new APRN practices in a state with a
collaborative agreement requirement. Which statement best
describes the APRN’s legal responsibilities when prescribing
controlled substances?
,A. The APRN can prescribe any controlled substance without
documentation if supervised by a physician.
B. The APRN must follow state regulations, document the
collaborative agreement, and comply with DEA registration and
state controlled-substance rules.
C. Federal law overrides state law, so state collaborative
agreements are optional.
D. The APRN only needs the collaborative agreement to
prescribe schedule III–V drugs, not schedule II.
Correct Answer: B
Rationale:
• Correct (B): APRNs must adhere to state scope-of-practice
and collaborative agreement requirements where
applicable, obtain appropriate DEA registration, and follow
state controlled-substance regulations.
• Incorrect (A): Supervision does not obviate necessary
documentation or regulatory compliance.
• Incorrect (C): Federal law does not negate state scope-of-
practice rules; state law often governs prescriptive
authority.
• Incorrect (D): Requirements vary by state; you cannot
assume schedule distinctions exempt collaborative
agreement needs.
Teaching Point: Know and document state and DEA
requirements before prescribing controlled drugs.
, Citation: Woo TM & Wright WL. Ch. 1, Legal & regulatory
aspects of prescribing. VitalSource+1
3
Reference: Ch. 1, Section: Clinical Judgment in Prescribing
Question Stem: A 72-year-old patient with multiple chronic
conditions is on eight chronic medications. The APRN is
concerned about polypharmacy. What is the best prescribing
action?
A. Continue all medications to avoid withdrawal and focus on
nonpharmacologic care.
B. Perform a targeted medication review, prioritize
deprescribing low-benefit drugs, and coordinate with the team.
C. Replace the oldest medications first, regardless of indication.
D. Stop all nonessential medications at once to reduce pill
burden quickly.
Correct Answer: B
Rationale:
• Correct (B): APRNs should conduct medication
reconciliation and targeted review, use evidence to
deprescribe low-benefit/ high-risk drugs, and collaborate
with the team to reduce polypharmacy safely.
• Incorrect (A): Blindly continuing polypharmacy risks
adverse events; nonpharmacologic care is important but
not a substitute for review.
Nurse Prescribers with Davis Edge
6th Edition
TEST BANK
Reference: Ch. 1, Section: The Role of the Advanced Practice
Nurse as Prescriber
Question Stem: An experienced APRN evaluates a new patient
with hypertension who is taking an over-the-counter herbal
supplement. Which action best reflects the APRN’s prescribing
responsibility?
A. Advise stopping all supplements and prescribe
antihypertensive medication immediately.
B. Document the supplement in the medication reconciliation,
assess for interactions, and consider this when selecting
therapy.
C. Ignore the supplement because OTC and herbal products are
not regulated the same as prescription drugs.
D. Refer the patient to a pharmacist and avoid prescribing until
the pharmacist assesses interactions.
Correct Answer: B
Rationale:
, • Correct (B): APRNs must perform medication
reconciliation, document OTC/herbal products, assess for
drug–drug interactions, and integrate this information into
rational drug selection; this aligns with safe prescribing
principles.
• Incorrect (A): Automatically stopping supplements without
assessment may harm rapport and is not evidence-based;
prescribers should evaluate risks/benefits first.
• Incorrect (C): OTC/herbal agents can interact with
prescribed drugs; dismissing them is unsafe.
• Incorrect (D): Collaboration with pharmacists is
appropriate, but the APRN retains responsibility for
prescribing decisions and should not abdicate them.
Teaching Point: Always reconcile and assess OTC/herbal
products before prescribing.
Citation: Woo TM & Wright WL. Ch. 1, The Role of the
Advanced Practice Nurse as Prescriber. VitalSource+1
2
Reference: Ch. 1, Section: The Role of the Advanced Practice
Nurse as Prescriber
Question Stem: A new APRN practices in a state with a
collaborative agreement requirement. Which statement best
describes the APRN’s legal responsibilities when prescribing
controlled substances?
,A. The APRN can prescribe any controlled substance without
documentation if supervised by a physician.
B. The APRN must follow state regulations, document the
collaborative agreement, and comply with DEA registration and
state controlled-substance rules.
C. Federal law overrides state law, so state collaborative
agreements are optional.
D. The APRN only needs the collaborative agreement to
prescribe schedule III–V drugs, not schedule II.
Correct Answer: B
Rationale:
• Correct (B): APRNs must adhere to state scope-of-practice
and collaborative agreement requirements where
applicable, obtain appropriate DEA registration, and follow
state controlled-substance regulations.
• Incorrect (A): Supervision does not obviate necessary
documentation or regulatory compliance.
• Incorrect (C): Federal law does not negate state scope-of-
practice rules; state law often governs prescriptive
authority.
• Incorrect (D): Requirements vary by state; you cannot
assume schedule distinctions exempt collaborative
agreement needs.
Teaching Point: Know and document state and DEA
requirements before prescribing controlled drugs.
, Citation: Woo TM & Wright WL. Ch. 1, Legal & regulatory
aspects of prescribing. VitalSource+1
3
Reference: Ch. 1, Section: Clinical Judgment in Prescribing
Question Stem: A 72-year-old patient with multiple chronic
conditions is on eight chronic medications. The APRN is
concerned about polypharmacy. What is the best prescribing
action?
A. Continue all medications to avoid withdrawal and focus on
nonpharmacologic care.
B. Perform a targeted medication review, prioritize
deprescribing low-benefit drugs, and coordinate with the team.
C. Replace the oldest medications first, regardless of indication.
D. Stop all nonessential medications at once to reduce pill
burden quickly.
Correct Answer: B
Rationale:
• Correct (B): APRNs should conduct medication
reconciliation and targeted review, use evidence to
deprescribe low-benefit/ high-risk drugs, and collaborate
with the team to reduce polypharmacy safely.
• Incorrect (A): Blindly continuing polypharmacy risks
adverse events; nonpharmacologic care is important but
not a substitute for review.
